These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 20551946)

  • 1. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O; Küry P; Kieseier B; Hartung HP
    Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
    Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
    Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC; Rausch M; Meier DP; Foster CA
    Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fingolimod treatment in multiple sclerosis].
    Tanaka M
    Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M; Amor S
    Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.